IRhythm Technologies’ Zio ambulatory cardiac monitors have the potential to change how doctors screen for irregular heartbeats by combining miniaturized biosensors and AI data analytics into a patch, CEO Quentin Blackford explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Blackford sits down with BI analyst Matt Henriksson for an in-depth interview on iRhythm, how its Zio platform technology, powered by its second-generation AI network, allows patients to be monitored without disrupting their everyday lives and how the recent Camelot trial data shows Zio to be more accurate and less costly to the health-care system than traditional monitors.